50 years.. and countless lives saved! Dr. Einhorn - we’re so grateful for you ♥️ #TesticularCancerCure #ResearchCureCancer @IUCancerCenter

📖 🔥New online from our group at @UTMDAnderson on ultra-precision oncology in #lungcancer 👉 Analysis from over 22,000 #EGFR-mutant tumor samples identified #PACC mutations in 12% of cases (A) 👉 While classical and #Ex20 mutations more commonly occur as single mutations, PACC mutations are more frequently (66%) observed as compound mutations (B). 👉 PACC/PACC and PACC/classical-like compound mutations function biologically similar to single PACC mutations, NOT classical mutations (C) 👉 Compound PACC mutations demonstrate greater sensitivity to EGFR TKIs than single PACC mutations (D) ⚡ 💡 Largest #EGFR mutation landscape in a Western population. ⚡ 💡 #Compound EGFR PACC Eare biologically analogous to #single PACC. ⚡ 💡 Important insights for drug development of next-generation EGFR TKIs.

Did we accidentally discover a synthetic lethal pair lol?

50% of #patients [w/ #cancer] positive for #germline variants did not meet @NCCN testing criteria, in a #PrecisionMedicine clinic providing #universal #germlinetesting to all #patients w/ common & rare #cancers 15% of all #patients had #pathogenic #germline #variants (PGVs) 13% of #patients w/ common #cancers (inc #breastcancer #lungcancer #CRC #pancreaticcancer #prostatecancer) 17% of #patients w/ rare #cancers (inc #sarcoma #braincancer #cholangiocarcinoma) c/w jamanetwork.com/journals/jam… #PiperNicolosi et al. @JAMAOnc ascopubs.org/doi/full/10.120… @beitsch et al. @JCO_ASCO ascopubs.org/doi/full/10.120… #NealShore et al. @JCOOP_ASCO jamanetwork.com/journals/jam… @WhitworthMD et al. @JAMANetworkOpen jamanetwork.com/journals/jam… @J_Samadder et al. @JAMAOnc mdpi.com/1422-0067/26/7/2839 #IsaacAilts et al. @MDPIOpenAccess ascopubs.org/doi/10.1200/JCO… @VivekSubbiah @Dr_R_Kurzrock @JCO_ASCO Overall, our data support #universal [#pancancer] #germlinetesting as a strategy to uncover clinically valuable information...including...#medical management, #targeted #treatment... #access #reducedisparities #genetictesting #precisionmedicine #precisiontherapy #clinicaltrials #precisionprevention ascopubs.org/doi/pdf/10.1200… #PhebeLemert @Dr_R_Kurzrock et al. @MedicalCollege @JCOOA_ASCO @ASCO

🆕@JCOPO_ASCO 💡Such a beautiful story of real world🌎 precision medicine. Meet➡️#ERRFI1🎯 📝Time to add➕this to ACTIONABLE Biomarkers🔐for #cholanagiocarcinoma @curecc. @NCCN 👇🏽Patient in paper, I took off hospice to give Erlotinib💊. @OncoAlert 🔗ascopubs.org/doi/10.1200/PO-…

Proud of my amazing team of dedicated residents, medical students, pharmacists, and fellows with four posters presented at @ASCO this year! A blessing to have such an incredibly hardworking, passionate, supportive, collegial, brilliant, and caring team who are all focused on changing outcomes for patients impacted by small cell lung cancer! @TheShieldsLab @IUCancerCenter @IUMedSchool @IUpulm @IUIntMed @IUHemOnc @PareshKumaaar @AAlfonsoMD @brookmarie99 @OncLive #SCLC #LCSM #teamwork #research

Congrats to the authors & Huge shoutout to @drshieldsmd for dropping masterclass insights on the top 4 #SCLC abstracts at #ASCO26 ❌CRT ChemoIO ES SCLC ⬆️toxic w/o benefit 🧠Tarlatamab: closing outcome gap in CNS SCLC 🔥Novel ADC IO: new hope to r/r SCLC @IUCancerCenter

Fascinating #ASCO26 data from Dr. Zhang (LORIN) Spatial transcriptomics pre/post neoadjuvant lorlatinib revealed potential combo strategies to target drug-tolerant persister cells🧬 High Ki67 / FOLR1 ➡️ pemetrexed or FOLR1 ADC combos? Universal high TROP2 ➡️ TROP2 ADC combos?

Congratulations Dr. Adra!!! 👏🏻 👏🏻👏🏻 @nabiladra

So proud of our team “Stealth Shields”🛡️for shining bright highlight novel research on ICI resistance mechanisms in lung cancer at the @ASCO @OncLive Fellows Forum. #meded

“What does your cancer research lab @TheShieldsLab at @IUCancerCenter study?” We focus exclusively on identifying new biomarkers, targets, and drugs for small cell lung cancer. Our goal is to help patients impacted by lung cancer live longer, fuller, and happier lives, as a result of our research. #research #supportresearch #lcsm #MDPhD #science

Have to say #ASCO26 is going to be an amazing update into all things RET for lung and other cancers. Do make sure you checkout these sessions /posters to be fully up to speed. You won’t regRET it… @ASCO @VivekSubbiah

Who made my Mt Rushmore of oncologists??? Well- first is Larry Einhorn- not just for curing testicular cancer but taking every doctors’ call for 50 yrs from around the world to help them with their challenging patients. But who else made my personal highlight list? You will need to listen to find out!

Nothing is more fulfilling than using your knowledge, skills, and talents in real time to help another person. Healthcare has many problems that still need fixing, but this will never change. Our patients need us and this field is worth fighting for.

Our first EVER Small Cell SMASHERS LIVE was absolutely AMAZING! Full of HOPE, HUGS & JOY! I am beyond grateful for this amazing community of kindness & love for those impacted by SCLC. Thank you to @LUNGevity for your generosity and heart as a partner to our @SclcSMASHERS!! Grateful to our sponsor @AmgenOncology for truly supporting our SMASHERS & their loved ones every step of their journey! #yougottafindyourpeople #voicesofhope #sclc #community #meded @lungoncdoc @nursesteagall @chrisdraft @ASridharMD @IUCancerCenter @UTSWMedCenter

A honor to be part of the NCCN panel for #SCLC representing @IUCancerCenter!

Thank you @IUCancerCenter for highlighting @TheShieldsLab research on a novel biomarker #ISL1 and new neuroendocrine subtype for #SCLC that predicts durable responses to lurbinectedin. 👏 More research on #ISL1 coming soon! 👀 So proud of our #team at @IUMedSchool @IUgradschool @IUIntMed @IUImpact in collaboration with @MoffittNews for their diligent work and dedication, leading to these meaningful discoveries! @ktgminton @PareshKumaaar @OTtheScientist @SclcSMASHERS @LUNGevity @OncodailyLung

Excellent talk from Bill Sellers on future directions with DepMap. Interesting differences between different PRMT5 inhibitors (SAM & MTA) and how they compare with selective inhibitors #aacr26

@DrShieldsMD at #TexasLung26: "Dawn of a revolution in therapy for SCLC". This year's slide shows the progress we've made. Look forward to @TheShieldsLab moving the needle for this aggressive cancer! @TLCconference

🎯👏🏻@FDAOncology 🙏🏼

From Indiana to Kenya, one physician helped change cancer care for thousands. Patrick Loehrer, MD, received the John W. Ryan Award for global impact through AMPATH Oncology. Read his story: ow.ly/6X0X50YzJGo.